Identification and Characterization of Immune Checkpoint Inhibitor–Induced Toxicities From Electronic Health Records Using Natural Language Processing
JCO Clinical Cancer Informatics · 2024-04 · (8)
DOI: 10.1200/cci.23.00151 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024-04. Verfasst von Hannah Barman und 12 weiteren Autor:innen. Beteiligte Einrichtung: nference, Cambridge, MA. Hauptthemen laut MEDLINE: Natural Language Processing, Electronic Health Records, Immune Checkpoint Inhibitors, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their use is associated with immune-related adverse events (irAEs). Estimating the prevalence and patient impact of these irAEs in the real-world data setting is critical for characterizing the benefit/risk profile of ICI therapies beyond the clinical trial population. Diagnosis codes, such as International Classification of Diseases codes, do not comprehensively illustrate a patient's care journey and offer no insight into drug-irAE causality. This study aims to capture the relationship between ICIs and irAEs more accurately by using augmented curation (AC), a natural language processing–based innovation, on unstructured data in electronic health records. METHODS In a cohort of 9,290 patients treated with ICIs at Mayo Clinic from 2005 to 2021, we compared the prevalence of irAEs using diagnosis codes and AC models, which classify drug-irAE pairs in clinical notes with implied textual causality. Four illustrative irAEs with high patient impact—myocarditis, encephalitis, pneumonitis, and severe cutaneous adverse reactions, abbreviated as MEPS—were analyzed using corticosteroid administration and ICI discontinuation as proxies of severity. RESULTS For MEPS, only 70% (n = 118) of patients found by AC were also identified by diagnosis codes. Using AC models, patients with MEPS received corticosteroids for their respective irAE 82% of the time and permanently discontinued the ICI because of the irAE 35.9% (n = 115) of the time. CONCLUSION Overall, AC models enabled more accurate identification and assessment of patient impact of ICI-induced irAEs not found using diagnosis codes, demonstrating a novel and more efficient strategy to assess real-world clinical outcomes in patients treated with ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- nference, Cambridge, MA.
- F. Hoffmann-La Roche, Basel, Switzerland.
- Department of Oncology, Mayo Clinic, Rochester, MN.
ORCID-Profile: Hannah Barman, Antonio Del Santo, Eli Silvert, Lisa A Kottschade, Matthew S Block, G Scott Chandler, Tyler E Wagner, Rajat Mohindra
Zitieren
APA
Barman, H., Venkateswaran, S., Santo, A. D., Yoo, U., Silvert, E., Rao, K., Raghunathan, B., Kottschade, L. A., Block, M. S., Chandler, G. S., Zalis, J., Wagner, T. E., & Mohindra, R. (2024). Identification and Characterization of Immune Checkpoint Inhibitor–Induced Toxicities From Electronic Health Records Using Natural Language Processing. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.23.00151
Vancouver
Barman H, Venkateswaran S, Santo AD, Yoo U, Silvert E, Rao K, et al. Identification and Characterization of Immune Checkpoint Inhibitor–Induced Toxicities From Electronic Health Records Using Natural Language Processing. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.23.00151
BibTeX
@article{Barman2024,
author = {Barman, Hannah and Venkateswaran, Sriram and Santo, Antonio Del and Yoo, Unice and Silvert, Eli and Rao, Krishna and Raghunathan, Bharathwaj and Kottschade, Lisa A and Block, Matthew S and Chandler, G Scott and Zalis, Joshua and Wagner, Tyler E and Mohindra, Rajat},
title = {Identification and Characterization of Immune Checkpoint Inhibitor–Induced Toxicities From Electronic Health Records Using Natural Language Processing},
journal = {JCO Clinical Cancer Informatics},
year = {2024},
number = {8},
doi = {10.1200/cci.23.00151}
}
EUVIMED